AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Immutep Limited, a late-stage immunotherapy company, received a €2,588,954 (~ A$4,567,769) research and development tax incentive payment from the French Government under its Crédit d’Impôt Recherche scheme. The payment is in respect of eligible R&D activities conducted in the European Union in 2024. Immutep qualifies for the tax incentive through its subsidiary Immutep S.A.S. due to research and development conducted in its French laboratory.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet